Efavirenz
Other / unclassified targets CARD8, CYP2B6, CYP3A4, CYP46A1 via activation
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | SUSTIVA | — | 2000-02-09 – 2013-05-02 | fda.gov ↗ |
| Approved | EU (EMA) | Stocrin | — | 1999-05-28 | europa.eu ↗ |
| Approved | US (FDA) | SUSTIVA | — | 1998-09-17 | fda.gov ↗ |
Trials 206 · started per year
Also used as a comparator or background therapy in 149 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT07341672 Comparator | Dec 2026 → Apr 2027 expected | — | Sunshine Lake Pharma Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04424264 Background | Dec 2019 → Oct 2020 | HIV infectious disease, tuberculosis | Professor Francois Venter | Completed | No outcome recorded |
| Phase 1 | NCT03706885 Comparator | May 2018 → Jan 2022 | — | Case Western Reserve University | Completed | No outcome recorded |
| Phase 1 | NCT02556268 Background | Feb → Dec 2016 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02631473 Comparator | Nov 2015 → Nov 2017 | HIV infectious disease | St Stephens Aids Trust | Suspended | No outcome recorded |
| Phase 1 | NCT01472380 Comparator | Nov → Dec 2011 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01187862 Background | Jul 2010 → Feb 2011 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01040091 Comparator | Dec 2009 → Apr 2014 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00399685 Comparator | Dec 2006 → Aug 2007 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00357188 Comparator | Jul → Sep 2006 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00266058 Comparator | Dec 2005 → Nov 2010 | HIV infectious disease, malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT00162097 Comparator | Nov 2004 → Mar 2008 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00032669 Background | Mar 2002 → Apr 2006 | HIV infectious disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02475915 Background | Jan → Nov 2015 | — | SEARCH Research Foundation | Completed | No outcome recorded |
| Phase 1/2 | NCT01632891 Background | Jan 2014 → Jun 2016 | HIV infectious disease, parasitemia | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 1/2 | NCT01668147 Comparator | Aug 2012 → Jun 2016 | drug-induced mental disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 224 trials | ||||||
| Phase 2 | NCT06338826 Background | Feb 2025 → Sep 2027 expected | HIV infectious disease | ANRS, Emerging Infectious Diseases | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02722421 Background | Apr 2017 → Dec 2019 | HIV infectious disease | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT02415595 Comparator | May 2015 → May 2016 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 2 | NCT02750059 Comparator | Jan 2015 → Feb 2018 | — | SEARCH Research Foundation | Completed | No outcome recorded |
| Phase 2 | NCT01789879 Comparator | Mar → Sep 2014 | HIV infectious disease | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT01632345 Comparator | Oct 2012 → Dec 2014 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01641809 Comparator | Aug 2012 → Oct 2013 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 2 | NCT01403051 Background | Sep 2011 → Feb 2013 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT01338883 Comparator | Jun 2011 → Dec 2012 | HIV infectious disease | Tobira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01489046 Background | Feb 2011 → Mar 2013 | HIV infectious disease | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT01254656 Comparator | Feb 2011 → Apr 2013 | — | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT01231555 Comparator | Nov 2010 → Jul 2011 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 2 | NCT00822315 Comparator | Jul 2009 → Nov 2011 | HIV infectious disease, tuberculosis | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 2 | NCT00903682 Comparator | Jun 2009 → Feb 2010 | AIDS | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 2 | NCT00752856 Comparator | Aug 2008 → May 2011 | HIV infectious disease | University of California, San Diego | Completed | No outcome recorded |
| Phase 2 | NCT01174914 Comparator | Mar 2008 → Mar 2010 | — | The Ojai Foundation | Completed | No outcome recorded |
| Phase 2 | NCT00476424 Comparator | Jun 2007 → Mar 2008 | HIV infectious disease | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
| Phase 2 | NCT00350272 Background | May 2006 → Aug 2007 | HIV infectious disease | Alexion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00110305 Comparator | Jun 2005 → Dec 2011 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 2 | NCT00100048 Comparator | Jan 2005 → Oct 2006 | AIDS | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00004852 Background | Sep 1999 → ? | HIV infectious disease | Glaxo Wellcome | Completed | No outcome recorded |
| Phase 2 | NCT00000912 Background | ? → May 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00001122 Background | ? → Oct 2003 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00031070 Background | ? → Dec 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT01837277 Comparator | Dec 2017 → Jul 2021 | immunodeficiency disease | Fundação Bahiana de Infectologia | Completed | No outcome recorded |
| Phase 2/3 | NCT02245022 Comparator | Mar 2017 → Dec 2018 | HIV infectious disease, pregnancy disorder | University of Liverpool | Completed | No outcome recorded |
| Phase 2/3 | NCT02285114 Background | Jan 2015 → Nov 2019 | — | Gilead Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT02489461 Comparator | Aug 2014 → Apr 2016 | HIV infectious disease | Viriom | Completed | No outcome recorded |
| Phase 2/3 | NCT00946595 Comparator | Nov 2009 → Jul 2013 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 2/3 | NCT00495326 Comparator | Dec 2007 → Apr 2011 | AIDS, tuberculosis | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 353 trials | ||||||
| Phase 3 | NCT04513379 Comparator | Nov 2020 → Oct 2022 | HIV infectious disease, tuberculosis | Shanghai Public Health Clinical Center | Unknown | No outcome recorded |
| Phase 3 | NCT04022967 Comparator | Sep 2020 → Feb 2025 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
| Phase 3 | NCT04303598 Background | Apr 2020 → May 2022 | HIV infectious disease | Henan Genuine Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03631732 Comparator | Aug 2018 → Aug 2019 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03249181 Comparator | Jan 2018 → Oct 2020 | HIV infectious disease, pregnancy disorder | University of Liverpool | Completed | No outcome recorded |
| Phase 3 | NCT03048422 Comparator | Jan 2018 → Oct 2020 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT03256422 Background | Sep 2017 → Aug 2019 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT03122262 Comparator | Jan 2017 → Apr 2022 | HIV infectious disease | Professor Francois Venter | Completed | No outcome recorded |
| Phase 3 | NCT02777229 Comparator | Jul 2016 → Jul 2018 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02616783 Comparator | Dec 2015 → Feb 2018 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02605954 Comparator | Nov 2015 → Jun 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02469246 Background | Jun 2015 → Dec 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02397096 Background | Jun 2015 → Feb 2018 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02345226 Comparator | Jan 2015 → Jun 2016 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02178592 Comparator | Jan 2015 → Nov 2017 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT02302547 Comparator | Dec 2014 → Aug 2017 | HIV infectious disease | University Hospital, Tours | Completed | No outcome recorded |
| Phase 3 | NCT03178084 Comparator | Oct 2014 → Nov 2016 | HIV infectious disease | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Completed | No outcome recorded |
| Phase 3 | NCT02157311 Background | Jul 2014 → Jan 2016 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02121795 Background | May 2014 → Aug 2015 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01709084 Comparator | Oct 2013 → Oct 2015 | HIV infectious disease | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 3 | NCT01435018 Background | Oct 2013 → Mar 2018 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 3 | NCT02670772 Background | Jul 2012 → Dec 2014 | AIDS | Willem Daniel Francois Venter | Completed | No outcome recorded |
| Phase 3 | NCT01516060 Comparator | Jan 2012 → Mar 2013 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 3 | NCT01495702 Comparator | Dec 2011 → Nov 2013 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01516970 Comparator | Nov 2011 → Aug 2013 | HIV infectious disease | Janssen-Cilag GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01011413 Comparator | Aug 2011 → Jun 2013 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 3 | NCT00984152 Comparator | Jun 2011 → Jun 2013 | HIV infectious disease | Rush University Medical Center | Withdrawn | No outcome recorded |
| Phase 3 | NCT00936195 Comparator | Jan 2010 → Jan 2013 | HIV infectious disease, pregnancy disorder | French National Agency for Research on AIDS and Viral Hepatitis | Withdrawn | No outcome recorded |
| Phase 3 | NCT00993031 Comparator | Dec 2009 → Jul 2013 | HIV infectious disease, malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00978068 Comparator | Sep 2009 → Jan 2013 | HIV infectious disease, malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00543725 Comparator | Jun 2008 → Jan 2010 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 3 | NCT00792324 Comparator | Jun 2008 → Aug 2009 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 3 | NCT00540449 Comparator | May 2008 → Feb 2010 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 3 | NCT00427297 Comparator | Sep 2007 → May 2009 | HIV infectious disease | University of Washington | Terminated | No outcome recorded |
| Phase 3 | NCT01805258 Comparator | Jun 2007 → Dec 2012 | tuberculosis | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00454337 Background | May 2007 → Sep 2008 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 3 | NCT00369941 Comparator | Aug 2006 → May 2009 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00332306 Comparator | Jun 2006 → Jun 2009 | HIV infectious disease, tuberculosis | Tuberculosis Research Centre, India | Unknown | No outcome recorded |
| Phase 3 | NCT00234091 Comparator | Apr 2006 → Sep 2011 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00302822 Background | Apr 2006 → Dec 2009 | AIDS | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 3 | NCT00280969 Comparator | Sep 2005 → Sep 2009 | HIV infectious disease | International Medical Center of Japan | Completed | No outcome recorded |
| Phase 3 | NCT00398996 Comparator | Jun 2005 → Jul 2010 | HIV infectious disease, pulmonary tuberculosis | Centre for the AIDS Programme of Research in South Africa | Completed | No outcome recorded |
| Phase 3 | NCT00098293 Comparator | Nov 2004 → Apr 2007 | — | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT00135343 Background | Apr 2004 → Oct 2005 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00116298 Background | Jan 2001 → Jan 2005 | AIDS | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00006208 Background | Aug 2000 → ? | HIV infectious disease | Triangle Pharmaceuticals | Unknown | No outcome recorded |
| Phase 3 | NCT00005918 Background | Jun 2000 → Apr 2002 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00158821 Background | Mar 2000 → Dec 2001 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00002362 Background | Aug 1999 → ? | HIV infectious disease | Triangle Pharmaceuticals | Suspended | No outcome recorded |
| Phase 3 | NCT00966160 Comparator | Jan 1999 → Dec 2008 | AIDS | University of Cologne | Completed | No outcome recorded |
| Phase 3 | NCT00002230 Background | — | HIV infectious disease | Northwestern University | Completed | No outcome recorded |
| Phase 3 | NCT00002393 Background | — | HIV infectious disease | Dupont Merck | Completed | No outcome recorded |
| Phase 3 | NCT00006154 Comparator | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 434 trials | ||||||
| Phase 4 | NCT07631897 Comparator | Jun 2026 → Jun 2028 expected | HIV infectious disease, tuberculosis | Shanghai Public Health Clinical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT02547844 Comparator | Sep 2015 → Oct 2016 | — | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02447016 Comparator | May 2015 → Dec 2016 | HIV infectious disease | Sheba Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT02057796 Background | Sep 2014 → Apr 2018 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 4 | NCT01900015 Comparator | Feb 2014 → Jan 2017 | HIV infectious disease, hepatitis C virus infection | Juan Macías | Completed | No outcome recorded |
| Phase 4 | NCT01147107 Comparator | Feb 2014 → Jun 2016 | HIV infectious disease, chronic hepatitis C virus infection | University of Hawaii | Completed | No outcome recorded |
| Phase 4 | NCT01989910 Comparator | Sep 2013 → Dec 2015 | HIV infectious disease | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT01694017 Comparator | Nov 2012 → Aug 2014 | HIV infectious disease | Tufts University | Completed | No outcome recorded |
| Phase 4 | NCT01585038 Comparator | Jul 2012 → May 2014 | cardiovascular disorder | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT01380080 Background | Oct 2011 → Jan 2015 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 4 | NCT01417988 Comparator | Aug 2011 → Jun 2013 | HIV infectious disease, tuberculosis | Prof JMA Lange | Terminated | No outcome recorded |
| Phase 4 | NCT01192035 Comparator | May 2011 → Sep 2014 | — | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT01194856 Comparator | Oct 2010 → Dec 2011 | HIV infectious disease, mitochondrial disease | The Cleveland Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT01340950 Comparator | Jul 2010 → Jul 2014 | HIV infectious disease, central nervous system disorder, dementia | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT01087814 Comparator | Feb → Sep 2010 | HIV infectious disease | University of Minnesota | Completed | No outcome recorded |
| Phase 4 | NCT00978237 Comparator | Oct 2009 → Nov 2013 | HIV infectious disease, localized lipodystrophy | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 4 | NCT00870363 Comparator | Apr 2009 → Apr 2013 | HIV infectious disease | University of California, Davis | Completed | No outcome recorded |
| Phase 4 | NCT00775606 Comparator | Oct 2008 → Dec 2010 | AIDS | Rush University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT00759070 Comparator | Sep 2008 → Jul 2013 | HIV infectious disease | Juan A. Arnaiz | Unknown | No outcome recorded |
| Phase 4 | NCT00615810 Comparator | Mar 2008 → Oct 2009 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00549198 Background | Jun 2007 → Dec 2009 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00444379 Comparator | Apr 2007 → Feb 2012 | HIV infectious disease, Kaposi's sarcoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT02028676 Comparator | Mar 2007 → Mar 2012 | HIV infectious disease | Medical Research Council | Completed | No outcome recorded |
| Phase 4 | NCT00335322 Comparator | Feb 2007 → Mar 2011 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT01049685 Comparator | Aug 2006 → Dec 2009 | HIV infectious disease | UPECLIN HC FM Botucatu Unesp | Unknown | No outcome recorded |
| Phase 4 | NCT00344760 Background | Jan 2005 → Mar 2007 | HIV infectious disease | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT00224458 Background | Sep 2004 → Feb 2006 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00256828 Background | Jun 2004 → Nov 2006 | HIV infectious disease | Clinical Trial Agency of HIV Study Group | Completed | No outcome recorded |
| Phase 4 | NCT01445223 Comparator | Apr 2004 → Dec 2009 | HIV infectious disease | Göteborg University | Completed | No outcome recorded |
| Phase 4 | NCT00127959 Background | Mar 2004 → Aug 2006 | HIV infectious disease, hepatitis B virus infection | International Antiviral Therapy Evaluation Center | Completed | No outcome recorded |
| Phase 4 | NCT00192595 Comparator | Jan 2004 → Jan 2007 | HIV infectious disease, hepatitis B virus infection | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT00342355 Comparator | Jan 2004 → Mar 2008 | HIV infectious disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 4 | NCT00643968 Comparator | Mar 2003 → Jun 2005 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00457665 Comparator | Feb 2002 → Oct 2007 | HIV infectious disease | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase not applicable16 trials | ||||||
| — | NCT05044962 Comparator | Nov 2021 → Mar 2027 expected | HIV infectious disease | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| — | NCT03405194 Comparator | May 2018 → May 2020 | HIV infectious disease | Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic | Withdrawn | No outcome recorded |
| — | NCT04463784 Comparator | Apr 2018 → Dec 2020 | HIV infectious disease, mental disorder | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT03251690 Comparator | Oct 2016 → Apr 2018 | HIV infectious disease, hyperlipidemia | Mahidol University | Completed | No outcome recorded |
| — | NCT02827643 Comparator | Jun 2016 → Mar 2017 | bone disorder | Mahidol University | Unknown | No outcome recorded |
| — | NCT01293123 Comparator | Dec 2011 → Jun 2013 | HIV infectious disease | University of California, San Diego | Terminated | No outcome recorded |
| — | NCT01479634 Comparator | Oct 2011 → Jun 2015 | HIV infectious disease | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT02002286 Background | Aug 2011 → May 2013 | HIV infectious disease | LI Taisheng | Completed | No outcome recorded |
| — | NCT01387022 Background | Jun 2011 → Nov 2014 | — | Centre for the AIDS Programme of Research in South Africa | Completed | No outcome recorded |
| — | NCT01318096 Comparator | Mar 2011 → Jul 2012 | HIV infectious disease | Yunnan AIDS Care Center | Unknown | No outcome recorded |
| — | NCT01277627 Comparator | Jan 2011 → Jul 2012 | hepatitis C virus infection | Valme University Hospital | Unknown | No outcome recorded |
| — | NCT00863668 Comparator | Mar 2009 → Mar 2010 | HIV infectious disease | University of Minnesota | Withdrawn | No outcome recorded |
| — | NCT00734344 Comparator | Sep 2008 → Aug 2012 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| — | NCT00661960 Comparator | Mar 2008 → Sep 2010 | AIDS | University of California, Davis | Completed | No outcome recorded |
| — | NCT00255840 Comparator | Jul 2006 → Jan 2009 | HIV infectious disease | CIPRA SA | Completed | No outcome recorded |
| — | NCT00051090 Background | — | HIV infectious disease, hepatitis B virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
Press releases naming this drug 18 releases
| Date | Issuer | Release |
|---|---|---|
| 2008-08-01 | Gilead Sciences | Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries gilead.com ↗ |
| 2007-12-17 | Gilead Sciences | European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection gilead.com ↗ |
| 2007-12-11 | Gilead Sciences | Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe gilead.com ↗ |
| 2007-10-18 | Gilead Sciences | European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) gilead.com ↗ |
| 2007-10-17 | Gilead Sciences | Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV gilead.com ↗ |
| 2007-07-23 | Gilead Sciences | 144-Week Data from Gilead's Study 934 Comparing Truvada(R) to Combivir(R) Both in Combination with Sustiva(R) Presented At International AIDS Society Meeting in Sydney gilead.com ↗ |
| 2006-12-15 | Gilead Sciences | 96-Week Data From Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination With Sustiva(R) Published in Journal of Acquired Immune Deficiency Syndrome gilead.com ↗ |
| 2006-10-09 | Gilead Sciences | Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) to European Medicines Agency gilead.com ↗ |
| 2006-09-28 | Gilead Sciences | Bristol-Myers Squibb and Gilead Sciences Establish Agreement to Commercialize ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada gilead.com ↗ |
| 2006-08-14 | Gilead Sciences | 96-Week Data from Gilead's Study 934 Comparing Viread(R) and Emtriva(R) to Combivir(R) Both in Combination with Sustiva(R) Presented at XVI International AIDS Conference gilead.com ↗ |
| 2006-07-12 | Gilead Sciences | U.S. Food and Drug Administration (FDA) Approves ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), The First Once-Daily Single Tablet Regimen for Adults with HIV-1 Infection gilead.com ↗ |
| 2006-04-27 | Gilead Sciences | Bristol-Myers Squibb and Gilead Sciences Submit New Drug Application to U.S. FDA for a Once-Daily Single Tablet Regimen of Sustiva(R) (Efavirenz) and Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Treatment gilead.com ↗ |
| 2006-01-09 | Gilead Sciences | Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva(R) (efavirenz) and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate) gilead.com ↗ |
| 2005-08-09 | Gilead Sciences | Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) and Sustiva(R) (Efavirenz) gilead.com ↗ |
| 2005-04-26 | Gilead Sciences | Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada -emtricitabine and tenofovir disoproxil fumarate- and Sustiva -efavirenz- gilead.com ↗ |
| 2005-02-03 | Gilead Sciences | Gilead Announces Preliminary 48-Week Data From Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Sustiva in Patients With HIV gilead.com ↗ |
| 2004-10-31 | Gilead Sciences | Interim 24-Week Data from Study 934 Comparing a Regimen of Viread and Emtriva Versus Combivir, Both in Combination with Efavirenz, in Patients with HIV Presented at 44th ICAAC gilead.com ↗ |
| 2004-08-26 | Gilead Sciences | Gilead Announces Preliminary 24-Week Data from Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Efavirenz In Patients With HIV gilead.com ↗ |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 377 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | efavirenz | “Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine,...” NCT00624195 ↗350“It may include one or two nucleoside reverse transcriptase inhibitors, such as zidovudine, didanosine, lamuvidine, zalcitabine, stavudine), a non- nucleoside reverse...” NCT00032669 ↗ “We administered the Basel phenotyping cocktail (caffeine, efavirenz, flurbiprofen, omeprazole, metoprolol, midazolam) to patients with liver cirrhosis (n = 16 Child A, n = 15...” PMID 37328712 ↗ Jun 2023 “Both HIV and HBV can be treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC), so we evaluated the safety and efficacy of combination antiretroviral therapy...” PMID 26831232 ↗ Feb 2016 “A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine,...” NCT00214435 ↗ “ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as...” NCT05044962 ↗ “Tenofovir / emtricitabine + efavirenz for all HIV-1-infected men and all HIV-1-infected women who meet the following requirements: on effective contraception and no history of...” NCT00495651 ↗ “Otherwise, patients can be initiated on a preferred regimen of tenofovir (TDF), emtricitabine (FTC), and efavirenz (EFV) according to the US Department of Health and Human...” NCT00799136 ↗ “Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.” NCT02002286 ↗ “The study-treatment were lopinavir/r 100/400mg bid or indinavir/r 100/400mg bid for PI-class, for NNRTI-class, efavirenz or nevirapine and all NRTIs except D4T and DDC at usual dosage.” NCT00122668 ↗ “Efficacy and Safety of Tenofovir Disoproxil Fumarate Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy for ART-naive Chinese Patients With HIV-1 Infection” NCT01844297 ↗ “A single tablet regimen (STR) of efavirenz, emtricitabine and tenofovir disoproxil fumarate (tenofovir DF) is the first complete HAART that is offered as one tablet once a day.” NCT00615745 ↗ “The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV).” NCT01509508 ↗ “A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period” NCT02652260 ↗ “currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg” NCT02591420 ↗ “Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks” NCT02670772 ↗ “Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz” NCT02827643 ↗ “probe drugs for simultaneous phenotyping of CYP1A2 (caffeine), CYP2B6 (efavirenz), CYP2C9 (losartan), 2C19 (omeprazole), CYP2D6 (metoprolol), and CYP3A4 (midazolam)” PMID 26123704 ↗ Jan 2016 “emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day” NCT00454337 ↗ “Efavirenz is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is a CNS-specific enzyme that metabolizes cholesterol to 24-hydroxycholesterol (24HC).” PMID 36581878 ↗ Dec 2022 “FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.” NCT01403051 ↗ “Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).” NCT00884793 ↗ “All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days” NCT01108926 ↗ “Tenofovir+Emtricitabine+Third agent (Including a non nucleoside reverse transcriptase inhibitor: efavirenz or nevirapine or etravirine or rilpivirine” NCT02302547 ↗ “Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular” NCT02397096 ↗ “Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime” NCT01309243 ↗ “Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.” PMID 32386721 ↗ May 2020 “A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)” NCT01867996 ↗ “once-daily oral fixed-dose combination of tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and efavirenz 600 mg” PMID 33010240 ↗ Oct 2020 “single-tablet regimen of efavirenz (600 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg)” PMID 28259776 ↗ Mar 2017 “efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP)” NCT02469246 ↗ “Allowed unboosted 3rd ARV agents: efavirenz (EFV), raltegravir (RAL), dolutegravir (DTG), or nevirapine (NVP)” NCT02285114 ↗ “600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily” NCT02556268 ↗ “The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.” NCT02028676 ↗ “Efavirenz (EFV) is the most widely used non-nucleoside reverse transcriptase inhibitor (NNRTI).” NCT03595709 ↗ “Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.” NCT00824421 ↗ “non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine” NCT03256422 ↗ “Fixed Dose Combination of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate” NCT01690403 ↗ “tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year” NCT01694017 ↗ “Efavirenz Oral Solution Given in Combination Antiretroviral Therapy (ART)” NCT00543530 ↗ “Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC)” NCT00752856 ↗ “HAART: The first line was Zidovudine(AZT)+Lamivudine(3TC)+Efavirenz(EFV)” NCT01344148 ↗ “efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF)” NCT02246998 ↗ “allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.” NCT01495702 ↗ “Sustiva (efavirenz 600 mg) once daily for oral administration” NCT00615810 ↗ “Period 1 Days 0-14 Daily efavirenz monotherapy 600 mg orally” NCT01136928 ↗ “Efavirenz (EFV) 600 mg tablet administered orally once daily” NCT01565889 ↗ “continue their efavirenz (EFV)-based antiretroviral regimen” PMID 27089862 ↗ Sep 2015 “NNRTI = efavirenz, rilpivirine, etravirine, doravirine” NCT06338826 ↗ “using efavirenz (EFV; 25 mg/kg of body weight/day)” PMID 28483965 ↗ Jun 2017 “Accepted NNRTIs: efavirenz (EFV), nevirapine (NVP)” NCT00039741 ↗ “pharmacokinetics of efavirenz (EFV), 600 mg daily” NCT02253823 ↗ “Efavirenz: 01 capsules day, plus NRTI background” NCT01049685 ↗ “Azidothimidine + lamivudine + efavirenz Or” NCT01174914 ↗ “or to efavirenz (EFV) at 600 mg QD” PMID 30352054 ↗ Oct 2018 “Tenofovir DF + Efavirenz (TDF+EFV)” NCT00643968 ↗ “efavirenz single dosing once daily” NCT01371006 ↗ “tenofovir/lamivudine/efavirenz” NCT02750059 ↗ “including Sustiva (efavirenz)” NCT00414635 ↗ “ART (efavirenz-based) only” NCT01417988 ↗ “efavirenz (EFV; Sustiva®)” NCT02121795 ↗ “unboosted efavirenz (EFV)” NCT06337032 ↗ “efavirenz (EFV; Sustiva®)” NCT02605954 ↗ “efavirenz (EFV;Sustiva®)” NCT02616783 ↗ “2. Efavirenz \[EFV\]” NCT01479634 ↗ “Efavirenz 600mg od” NCT02245022 ↗ “Efavirenz (EFV)” NCT02178592 ↗ “Drug: Efavirenz” NCT00350272 ↗ “efavirenz (EFV)” NCT03631732 ↗ “efavirenz,” NCT02157311 ↗ “Efavirenz” NCT00737724 ↗ |
| Known as | DMP-266 | “Viracept (Nelfinavir Mesylate) 1250 Mg BID, Crixivan (Indinavir Sulfate) 1200mg q12h, and Sustiva (Efavirenz; DMP-266) 600 Mg q24h” NCT00002235 ↗5“Sustiva (Efavirenz; DMP-266)” NCT00002419 ↗ “Sustiva (Efavirenz; DMP-266)” NCT00002234 ↗ “Efavirenz (EFV, DMP-266)” NCT00001086 ↗ “DMP 266 (Efavirenz, EFV)” NCT00001087 ↗ “DMP 266 (Efavirenz)” NCT00000893 ↗ |
| Known as | efavirenz (Sustiva) | “efavirenz (Sustiva)” NCT00884793 ↗1“efavirenz: Sustiva” NCT01318096 ↗ |
| Known as | Efavirenz component of atripla | ChEMBL registry synonym — accepted as the source's own label CHEMBL223228 ↗ |
| Known as | Efavirenz component of symfi | ChEMBL registry synonym — accepted as the source's own label CHEMBL223228 ↗ |
| Known as | Efavirenz component of telura | ChEMBL registry synonym — accepted as the source's own label CHEMBL223228 ↗ |
| Known as | Efavirenz Stocrin (EFVBMM) | “Efavirenz Stocrin (EFVBMM)” NCT00444379 ↗ |
| Known as | Efavirenz teva | ChEMBL registry synonym — accepted as the source's own label CHEMBL223228 ↗ |
| Known as | Efavirenzum | ChEMBL registry synonym — accepted as the source's own label CHEMBL223228 ↗ |
| Known as | EFV | “DESIGN: ICE-001 is a phase IV, randomized, two-arm unblinded study, comparing the effect on immune reconstitution of open-label ritonavir (RTV)-enhanced lopinavir (LPV) to...” NCT00775606 ↗111“The Intensive Pharmacokinetics Sub-study of Encore1: A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Compare the Safety and Efficacy of Reduced Dose Efavirenz...” NCT01271894 ↗ “The purpose of this study is to compare long-term safety and tolerability of stavudine (d4T) extended release (ER) versus conventional (immediate release [IR]) formulations,...” NCT00116298 ↗ “Daily Antiretroviral Therapy (DART-II): An Open-Label, Single-Arm, Prospective, Multicenter Clinical Trial To Evaluate the Efficacy and Safety fo Stavudine Extended Release...” NCT00116116 ↗ “Both HIV and HBV can be treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC), so we evaluated the safety and efficacy of combination antiretroviral therapy...” PMID 26831232 ↗ Feb 2016 “In the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2010/VESTED study, pregnant women were randomized to initiate dolutegravir (DTG) +...” PMID 38877762 ↗ Nov 2024 “This 96 week, Phase 2b study in 150 HIV-1 infected antiretroviral (ART) naive adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and...” NCT01231555 ↗ “This will be a two-center, placebo controlled blinded clinical trial to evaluate the safety and tolerability of efavirenz (EFV) in 36 clinically stable subjects with mild...” NCT03706885 ↗ “BACKGROUND: Study 903 is a phase 3 trial with a completed 144-week, double-blind phase comparing tenofovir DF (TDF) with stavudine (d4T), in combination with lamivudine (3TC)...” PMID 18042503 ↗ Nov 2007 “Adult AIDS Clinical Trials Group 5043 examined pharmacokinetic (PK) interactions between amprenavir (APV) and efavirenz (EFV) both by themselves and when nelfinavir (NFV),...” PMID 16048950 ↗ Aug 2005 “The purpose of this study is to see if it is safe and effective to give HIV-positive patients a combination of anti-HIV drugs (abacavir \[ABC\] plus efavirenz \[EFV\] plus...” NCT00005018 ↗ “The goal of this clinical trial is to see if Efavirenz (EFV) intensification to a baseline combination antiretroviral regimen (cART) can help reduce the size of the latent...” NCT07193875 ↗ “This study aims to evaluate the safety and effectiveness of the tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + efavirenz (EFV) regimen in antiretroviral therapy...” NCT01844297 ↗ “The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been...” PMID 18781872 ↗ Oct 2008 “The Induction Phase consists of a 24 week dose-ranging evaluation of GSK1265744 at blinded doses of 10 mg, 30 mg and 60 mg once-daily and a control arm of open-label efavirenz...” NCT01641809 ↗ “Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720...” NCT00016718 ↗ “We studied the safety and efficacy of once-daily NVP, compared with efavirenz (EFV; standard therapy); both drugs were administered in combination with 2 nucleoside...” PMID 21890776 ↗ Oct 2011 “Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB...” NCT00398996 ↗ “BACKGROUND: In the ECHO/THRIVE 96-week efficacy analysis, the response rate was 78% with rilpivirine (RPV) and efavirenz (EFV) plus two nucleoside/nucleotide reverse...” PMID 23714781 ↗ May 2013 “For this study, the following HIV treatment (or HAART) were provided in the form of a single tablet that contains three different drugs: efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF).” NCT01403051 ↗ “The plasma concentration of patients treated with efavirenz (EFV) 600 mg was found to exceed the upper limit of the proposed therapeutic window in most Chinese HIV-infected individuals” PMID 33485301 ↗ Jan 2021 “Patients receive specific combinations of 3 or 4 of the following 6 drugs: didanosine (ddI), stavudine (d4T) efavirenz (EFV), nelfinavir (NFV), lamivudine (3TC), or zidovudine (ZDV).” NCT00000919 ↗ “The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV).” NCT01509508 ↗ “A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period” NCT02652260 ↗ “Arm 1 (integrated arm) participants will receive didanosine (ddI), efavirenz (EFV), and lamivudine (3TC) once daily concurrent with standard TB therapy.” NCT00091936 ↗ “A Feasibility Study of Lamivudine/Zidovudine (3TC/ZDV) Plus Efavirenz (EFV) as Initial Therapy of HIV-1 Infected Patients in a Rural Area of China” NCT00100594 ↗ “open-label lopinavir/ritonavir (LPV/r) at a dose of 533/133 mg twice a day and efavirenz (EFV) at a dose of 600 mg/d (the nucleoside-sparing arm)” PMID 17527093 ↗ Jun 2007 “A Pilot Study of Safety, Effectiveness, and Adherence of Lamivudine/Zidovudine and Efavirenz (3TC/ZDV + EFV) to Treat HIV-1 Infection in Senegal” NCT00100568 ↗ “Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime” NCT01309243 ↗ “The fixed-dose combination of Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV or Atripla®) is a highly effective HAART combination” NCT00936195 ↗ “Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir Regimens” NCT07631897 ↗ “Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)” NCT00495326 ↗ “Arm A: APV plus saquinavir soft gel capsule (SQVsgc) plus abacavir (ABC) plus efavirenz (EFV) plus adefovir (ADV).” NCT00000912 ↗ “In Arm A, patients will receive lopinavir/ritonavir (LPV/r) twice daily and efavirenz (EFV) once daily before bed.” NCT00050895 ↗ “certain anti-HIV drugs (efavirenz \[EFV\] and nelfinavir \[NFV\]) affect the amount of certain fat-lowering drugs” NCT00017758 ↗ “Lopinavir/ritonavir (LPV/r), a PI, and efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI)” NCT00075907 ↗ “efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP)” NCT02469246 ↗ “Allowed unboosted 3rd ARV agents: efavirenz (EFV), raltegravir (RAL), dolutegravir (DTG), or nevirapine (NVP)” NCT02285114 ↗ “Current guideline recommend efavirenz (EFV) 600mg per day as the first of choice for HIV/TB co-infection.” NCT04513379 ↗ “The other anti-HIV drugs used are abacavir (ABC), amprenavir (APV), ritonavir (RTV), and efavirenz (EFV).” NCT00002239 ↗ “Efavirenz (EFV) has been associated with torsade de pointes despite marginal QT interval lengthening.” PMID 27333947 ↗ Jul 2016 “Efavirenz (EFV) is the most widely used non-nucleoside reverse transcriptase inhibitor (NNRTI).” NCT03595709 ↗ “d4T 20 mg twice daily and TDF, taken in combination with lamivudine (3TC) and efavirenz (EFV).” PMID 30640204 ↗ Feb 2019 “Optimizing efavirenz (EFV) dosing to minimize adverse events (AEs) remains a critical issue.” PMID 42235914 ↗ Jun 2026 “ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)” NCT00427297 ↗ “plus 1 NNRTI (non-nucleoside reverse transcriptase inhibitor), which is EFV (Efavirenz)” NCT03251690 ↗ “the effect of Efavirenz (EFV) 600 mg daily on the QT/QTc interval will be evaluated.” NCT00744809 ↗ “co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)” NCT01435018 ↗ “Four 100mg Etravirine tablets plus one Efavirenz (EFV) placebo tablet once daily” NCT00792324 ↗ “once-daily tenofovir DF plus emtricitabine (TDF/FTC) with efavirenz (EFV).” PMID 18474495 ↗ Mar 2008 “Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC)” NCT00752856 ↗ “HAART: The first line was Zidovudine(AZT)+Lamivudine(3TC)+Efavirenz(EFV)” NCT01344148 ↗ “The study-specified NNRTIs will be nevirapine (NVP) or efavirenz (EFV).” NCT00000922 ↗ “Patients also receive open-label efavirenz (EFV) and lamivudine (3TC).” NCT00005918 ↗ “efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF)” NCT02246998 ↗ “in Combination With Lamivudine (3TC) and Efavirenz (EFV) Once Daily” NCT00116415 ↗ “abacavir (ABC)/lamivudine (3TC)/zidovudine (ZDV)/efavirenz (EFV)” NCT00013520 ↗ “Arm 1: Zidovudine (AZT), emtricitabine (FTC), efavirenz (EFV)” NCT00127959 ↗ “Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)” NCT00364793 ↗ “Efavirenz (EFV) 600 mg tablet administered orally once daily” NCT01565889 ↗ “Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)” NCT02273765 ↗ “Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)” NCT00365612 ↗ “Tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV)” NCT00759070 ↗ “tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV)” NCT00335322 ↗ “efavirenz (EFV) 600 mg q.d. administered for 14 days.” NCT01268839 ↗ “either efavirenz (EFV) or lopinavir/ritonavir (LPV/r)” NCT00100581 ↗ “Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)” NCT00192595 ↗ “Accepted NNRTIs: efavirenz (EFV), nevirapine (NVP)” NCT00039741 ↗ “pharmacokinetics of efavirenz (EFV), 600 mg daily” NCT02253823 ↗ “Tenofovir + Lamivudine + Efavirenz (TDF+3TC+EFV)” NCT04022967 ↗ “the anti-HIV drug efavirenz (EFV) will be tested” NCT00000914 ↗ “Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)” NCT02632474 ↗ “TDF/FTC plus either efavirenz (EFV) or ZDV” PMID 23639243 ↗ Apr 2013 “Tenofovir DF + Efavirenz (TDF+EFV)” NCT00643968 ↗ “TDF/FTC/efavirenz (EFV) groups” PMID 38978403 ↗ Jul 2024 “Reduced Dose Efavirenz (EFV)” NCT01451333 ↗ “unboosted efavirenz (EFV)” NCT06337032 ↗ “efavirenz (EFV; Sustiva®)” NCT02605954 ↗ “Efavirenz (EFV, DMP-266)” NCT00001086 ↗ “DMP 266 (Efavirenz, EFV)” NCT00001087 ↗ “efavirenz (EFV;Sustiva®)” NCT02616783 ↗ “3TC/ABC/efavirenz (EFV)” NCT00005017 ↗ “efavirenz (EFV)/FTC/TDF” PMID 30101539 ↗ Aug 2018 “efaviren (EFV; 600 mg)” NCT00112047 ↗ “Efavirenz (EFV) 600mg” NCT01583439 ↗ “2. Efavirenz \[EFV\]” NCT01479634 ↗ “efavirenz (EFV)” NCT03631732 ↗ “Efavirenz (EFV)” NCT01040091 ↗ “efavirenz (EFV)” NCT00002419 ↗ “Efavirenz (EFV)” NCT00122538 ↗ “Efavirenz (EFV)” NCT00802802 ↗ “Efavirenz (EFV)” NCT00192660 ↗ “efavirenz (EFV)” PMID 20455766 ↗ May 2010 “Efavirenz (EFV)” NCT01146873 ↗ “Efavirenz (EFV)” NCT01011413 ↗ “efavirenz (EFV)” NCT00001122 ↗ “efavirenz (EFV)” NCT00799136 ↗ “Efavirenz (EFV)” NCT00158405 ↗ “Efavirenz (EFV)” NCT01571414 ↗ “Efavirenz (EFV)” NCT00992069 ↗ “efavirenz (EFV)” PMID 19512937 ↗ Aug 2009 “efavirenz (EFV)” NCT00005000 ↗ “EFV (Efavirenz)” NCT00828789 ↗ “Efavirenz (EFV)” NCT00158457 ↗ “Efavirenz (EFV)” NCT00978068 ↗ “efavirenz (EFV)” NCT00002362 ↗ “Efavirenz (EFV)” NCT02178592 ↗ “efavirenz (EFV)” NCT00903682 ↗ |
| Known as | EFV: Efavirenz | “EFV: Efavirenz” NCT01805258 ↗ |
| Known as | EFV: efavirenz, Sustiva | “EFV: efavirenz, Sustiva” NCT02028676 ↗ |
| Known as | EFZ | “A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)” NCT01867996 ↗1“efavirenz (EFZ) and nelfinavir (NFV)” NCT00000893 ↗ |
| Known as | L-743726 | ChEMBL registry synonym — accepted as the source's own label CHEMBL223228 ↗ |
| Known as | NANO-efavirenz | “a new pharmaceutical formulation of efavirenz (NANO-efavirenz) in HIV negative healthy volunteers after single dose and a steady-state.” NCT02631473 ↗ |
| Known as | NSC-742403 | ChEMBL registry synonym — accepted as the source's own label CHEMBL223228 ↗ |
| Known as | Stocrin | “Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)” NCT00335322 ↗2“plus EFV (Stocrin) 600 mg orally once daily at bedtime” NCT01435018 ↗ “efavirenz (Sustiva/Stocrin) 400 mg once daily” NCT02832778 ↗ |
| Known as | Susitiva | “The purpose of the study is to examine the effect of switching from an antiretroviral combination that includes efavirenz (Susitiva®), in individuals experiencing...” NCT00792324 ↗ |
| Known as | Sustiva | “In this study, we have chosen as BID regimen that containing NNRTI efavirenz (Sustiva®) and Combivir® which is the commercial combination of the NRTI zidovudine + lamivudine,...” NCT00256828 ↗24“A Phase I/II, Open Label Study to Evaluate the Ability of Combination Therapy With ABT-378/Ritonavir (Kaletra), Lamivudine (Epivir), Efavirenz (Sustiva)and Tenofovir DF to...” NCT00038220 ↗ “Canadian Sustiva Oral Liquid Expanded Access Program: An Open-Label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP266)” NCT00162188 ↗ “Viracept (Nelfinavir Mesylate) 1250 Mg BID, Crixivan (Indinavir Sulfate) 1200mg q12h, and Sustiva (Efavirenz; DMP-266) 600 Mg q24h” NCT00002235 ↗ “To assess the bioequivalence of a selected single-dose of NANO-efavirenz to a single dose 600mg of efavirenz as Sustiva®” NCT02631473 ↗ “QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)” NCT00727597 ↗ “administration of 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 1” NCT00810303 ↗ “Efavirenz 600 mg, (Sustiva, Bristol-Myers Squibb) once daily” NCT00759070 ↗ “600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb)” NCT00966160 ↗ “most common is Sustiva, which is also called efavirenz.” NCT01087814 ↗ “efavirenz (Sustiva/Stocrin) 400 mg once daily” NCT02832778 ↗ “Efavirenz (Sustiva®) 600 mg a Day” NCT02253823 ↗ “including Sustiva (efavirenz)” NCT00414635 ↗ “Sustiva (Efavirenz; DMP-266)” NCT00002419 ↗ “Sustiva (Efavirenz) 600mg QD” NCT00004585 ↗ “Sustiva (Efavirenz; DMP-266)” NCT00002234 ↗ “efavirenz (EFV; Sustiva®)” NCT02605954 ↗ “efavirenz (EFV;Sustiva®)” NCT02616783 ↗ “Sustiva® (efavirenz)” NCT00075231 ↗ “Efavirenz (Sustiva)” NCT00457665 ↗ “Sustiva (efavirenz)” NCT00121017 ↗ “Sustiva (Efavirenz)” NCT00002447 ↗ |
| Known as | Sustiva (efavirenz) | “Sustiva (efavirenz)” NCT00523458 ↗ |
| Known as | Sustiva 600 | ChEMBL registry synonym — accepted as the source's own label CHEMBL223228 ↗ |
| Known as | Viraday | ChEMBL registry synonym — accepted as the source's own label CHEMBL223228 ↗ |
| Action | Inhibit | “efavirenz (an NNRTI, non-nucleoside reverse transcriptase inhibitor)” NCT00000918 ↗ |
| Modality | Other / unclassified | “Non-Nucleoside Reverse Transcriptase Inhibitor” NCT00000919 ↗ |
| Route | Oral | “efavirenz 600 mg po QD” NCT00001766 ↗ |
| Target | CYP2B6 | “Efavirenz serves as a model substrate, inhibitor and inducer of CYP2B6 (and other drug disposition proteins).” NCT02401256 ↗ |